The top 5 pharma M&A deals of 20202020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout Share XThe top 5 pharma M&A deals of 2020https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/
How companies can encourage more diversity and inclusion in pharmaSeptember is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares Share XHow companies can encourage more diversity and inclusion in pharmahttps://pharmaphorum.com/views-analysis-patients/how-companies-can-encourage-more-diversity-and-inclusion-in-pharma/
MSD’s David Peacock on moving UK healthcare forwardDavid Peacock has worked across the world for MSD and other companies, and has now taken the helm Share XMSD’s David Peacock on moving UK healthcare forwardhttps://pharmaphorum.com/views-analysis-sales-marketing/msds-david-peacock-on-moving-uk-healthcare-forward/
EU regulators approve AstraZeneca’s Lynparza in pancreatic cancerThe European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation. Approval in metastatic Share XEU regulators approve AstraZeneca’s Lynparza in pancreatic cancerhttps://pharmaphorum.com/news/eu-regulators-approve-astrazenecas-lynparza-in-pancreatic-cancer/
NICE rejects MSD/Pfizer’s combination in untreated kidney cancerNICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) Share XNICE rejects MSD/Pfizer’s combination in untreated kidney cancerhttps://pharmaphorum.com/news/nice-rejects-msd-pfizers-combination-in-untreated-kidney-cancer/
NICE backs Lynparza across the board for BRCA+ovarian cancerAstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance Share XNICE backs Lynparza across the board for BRCA+ovarian cancerhttps://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
AZ/MSD’s Lynparza sees positive results in prostate cancerAstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant Share XAZ/MSD’s Lynparza sees positive results in prostate cancerhttps://pharmaphorum.com/news/az-msds-lynparza-sees-positive-results-in-prostate-cancer/
